CHI no .....
First name ..... DOB ....
Last name ..... Sex: ☐ M ☐ F
Address

or attach addressograph label here

Service/Hospitals/Dept. etc.
Ward/Team: .....

NHS Lanarkshire

Appendix 2 - **Blanket** Unlicensed & High Risk Off Label Medicine Application

Date: .... Time: .... (24 hour)

Identifies as .....

Application Form

This form is to be used in conjunction with the NHS Lanarkshire Policy for Unlicensed Medicines.
Before completion, you must have read this policy which identifies your responsibilities.

Requester details

Prescriber name:		Hospital site: Ward/Outpatient dept:
Speciality:		
Contact details:		Date requested: Date required:

Patient details

Anticipated usage (please tick) - Estimated patient numbers:

☐ For your patients only
☐ For patients within your speciality on a single site
☐ For patients within your speciality on all sites
☐ Any patient within the Health Board

Unlicensed Medicine Details

Product name:
(International Non Proprietary Name)

Proprietary Name (if known):

Strength and Pharmaceutical Form:

Manufacturer (if known):

Indication:

Dose/frequency/route:

Duration of Treatment:

Category of request:

1. The intended use of the medicine is outside of the marketing authorisation for a licensed medicine (off-label prescribing) and is considered 'high risk' in Appendix 4 ☐
2. The medicine is an unlicensed medicine as described in the above policy ☐

If the medicine is unlicensed – please complete the following

Why is an unlicensed medicine being considered? (Tick as appropriate):

1. There is no UK licensed product available to treat or diagnose medical condition. ☐
2. The UK licensed product used to treat or diagnose the medical condition is temporarily unavailable ☐
3. The UK licensed product used to treat or diagnose the medical condition is unsuitable ☐
4. No therapeutically equivalent UK licensed product available or suitable (provide details): ☐
5. Patient Safety: ☐
6. Other (provide details):

Was a product licence in the UK withdrawn? ☐ Yes ☐ No ☐ Not known
If yes, contact manufacturer to find out reasons for withdrawal.

SAMPLE

NMAHP:BU&HTO.24_24515.L

Pub. date: Aug. 2024 | Review date: Aug. 2029 | Issue No: 01

Patient name:	CHI number:

Clinical Evidence			
Is there any evidence to support its use for the proposed indication?	☐ Yes	☐ No	
Is there evidence to support its proposed administration schedule? (dose, duration, concentration for parenteral products and route)	☐ Yes	☐ No	
Is the active drug currently in a licensed product for use via the same route of administration e.g. tablet, suspension?	☐ Yes	☐ No	
Is the product licensed for the specified indication in another country?	☐ Yes	☐ No	☐ Not known
UK product licence applied for? If yes, record date of application for licence:	☐ Yes	☐ No	☐ Not known
Are other Boards using this medicine? If so, name:	☐ Yes	☐ No	☐ Not known
Summarise below the supporting evidence, list references and attach copies of references where available.			
What are the risks to the patient of not using this drug?			
What side effects **and** significant interactions have been reported? Is any monitoring required? Describe:			
Give details of contraindications and any other risks to the patient. Include precautions in use.			
Will there be any primary care implications? (e.g. need for a shared care protocol) If so, describe:			

SAMPLE

Patient name:	**CHI number:**

Prescriber ☐ **Consultant** ☐ **Specialist Registrar (SpR)** ☐ **GP or** ☐ **other prescriber (Tick one)**	
Print name:	Speciality/Directorate:
Signature:	Date:
If SpR, state name of patient's consultant:	

Authorisation of Application (pharmacy – acute senior pharmacist or locality prescribing adviser)		
Name	Designation	Signature & Date

Medicines Cost (Medicines costing less than £5,000 per patient/year will follow usual Community Pharmacy processes in primary care or go straight to Final Process Approval below for acute requests)	
For medicines costing more than £5,000 but less than £25,000 per patient/year? ☐ Yes ☐ No Approved by acute site Chief of Medicine, or Associate Director (Primary Care)	Signature
For medicines costing more than £25,000 per patient/year? ☐ Yes ☐ No Approved by acute site Chief of Medicine AND Medical Director, or Associate Director (Primary Care)	Signature Signature

Final process approval
Approval for use ☐ Yes ☐ No Date: ....
If no, give reasons
State restrictions on prescribing/use
Any further Information

Completed by: (PRINT NAME)	**Designation of approver:**
Signature:	**Date:** .... **Time:** ....

SAMPLE